Navigation Links
Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Date:4/7/2009

DENVER, April 7 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO), has been selected as one of the presenting companies at the Company Showcase during BIOZONA 2009 - Arizona's Annual Bioscience Industry Conference at the Sheraton Phoenix Downtown on April 7th in Phoenix, Arizona.

Matthew B. Wiener, PharmD, COO and Founder of Pharmatech Oncology, will present during the first session of the conference. The presentation will cover topics including: the science, business and markets on which the company is based, recent accomplishments, and strategic partnerships.

Dr. Wiener will focus on the many accomplishments for Pharmatech Oncology in cancer clinical trials utilizing the Just-In-Time (JIT) enrollment methodology. The aim of the Just-In-Time program is to shorten the time to enroll cancer patients into clinical trials and also expand the number of patients being offered trials. "Pharmatech Oncology is honored to be selected from a large number of applicants to be one of eighteen companies presenting at this distinguished BIOZONA event. We anticipate great exposure for our Just-In-Time clinical trial program, as we feel it is revolutionizing the enrollment process of adult cancer patients into clinical trials," states Dr. Wiener. For further information about BIOZONA 2009, please visit the event web site at http://www.azbio.org/Biozona2009.asp.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. With Data Management as a separate business entity, it allows for management of data for other types of research aside from strictly oncology. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.

Key Words: Oncology, Clinical Trials, Cancer, Patients, Contract Research, Site Management, Data Management, Research, Network, Just-In-Time, BIOZONA


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
2. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
3. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
4. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
7. Pharmatech 2.0: Introducing Pharmatech Oncology
8. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Announces Third Quarter 2008 Results
11. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... - FACIT announced a seed stage investment in ... created by FACIT focused on developing a portfolio ... non-dilutive capital, achieves a targeted $3.0M financing for ... to accelerate the nomination of a candidate drug ... a strategic partnership for clinical trials in patients ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
Breaking Biology Technology:
(Date:2/27/2017)... , Feb. 27, 2017   Strategic Cyber Ventures ... it has led a $3.5 million investment in  Polarity ... Strategic Cyber Ventures is DC based and is led ... Hank Thomas . Ron Gula , also a ... also participated in this series A round of funding. ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):